公司资料
Jaguar Health 股价、新闻与催化剂
- 股票代码:
- JAGX
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
2.75 USD (-21.28%)
收盘价
最后更新: 2026年9月17日
2.12M USD
市值
股价为何变动
截至 2026年9月17日，JAGX 下跌 21.3%，收于 $2.75。当前新闻监测窗口内未发现新的同公司新闻。
公司概览
业务概览
Jaguar Health is a biopharmaceutical company focused on gastrointestinal and rare-disease therapies, with Mytesi as a key commercial asset. Its story combines niche commercialization with a pipeline aimed at high-unmet-need GI indications.
所在地与行业分类
Jaguar Health is headquartered in the United States and listed on NASDAQ. It sits in specialty biopharma with a GI and rare-disease profile.
商业模式特征
The business depends on product sales, label or indication expansion, and the ability to keep a narrow franchise financed. Investors usually watch commercial traction, regulatory progress, and pipeline updates.
生物医药行业定位
Jaguar occupies a niche GI-specialty position within biotech. Its stock tends to move on commercial execution and the market's view of whether the portfolio can expand beyond a single product.
未来催化剂
- The next few months for Jaguar Health are centered on its latest development priorities. The latest company update points to commercial rights for Mytesi ® and Canalevia ® -CA1 Company continues its focus on crofelemer development efforts for rare-disease intestinal failure indications. If that progress holds, the program should stay on the radar through the rest of the quarter. The partnership angle also matters here, especially around Q4 2025, buoyed by license of U.S.
近期新闻
新闻标题由机器翻译，详情为英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。